Skip to Content

Telavancin Pregnancy and Breastfeeding Warnings

Telavancin is also known as: Vibativ

Telavancin Pregnancy Warnings

Animal studies have revealed evidence of reduced fetal weights, increased rates of digit and limb malformations in offspring, and increased number of stillborn pups. This drug did not affect the fertility, mating, or reproductive performance of adult male and female rats, but male rats displayed altered sperm quantity and quality that were reversible following an 8-week recovery period. There are no controlled data in human pregnancy. US: To monitor the outcomes of pregnant women exposed to this drug, a pregnancy registry has been established. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-855-633-8479. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

UK: Use during pregnancy is contraindicated. US: Avoid use during pregnancy unless the benefits to the patient outweigh the potential risks to the fetus. Comments: A serum pregnancy test should be obtained prior to treatment initiation and effective contraception should be used during therapy in women of childbearing potential. US FDA pregnancy category: C

See references

Telavancin Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the benefit of breastfeeding to the child and the benefit of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant are unknown.

This drug is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants due to its poor oral absorption. However, an alternative medication may be considered during breastfeeding as there is no lactation literature available for this drug.

See references

References for pregnancy information

  1. "Product Information. Vibativ (telavancin)." Theravance Inc, South San Francisco, CA.

References for breastfeeding information

  1. "Product Information. Vibativ (telavancin)." Theravance Inc, South San Francisco, CA.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.